Released Nov 8, 2012, after the close
10-Q filed Nov 9, 2012, 40 days after period end · 0001019687-12-003931
Q3 2012 · 10-Q
Revenue$6.05M$6.05M +3.0% vs Q3 2011+100,481.9% vs Q2 2012
Net Income$54.00K$54.00K N/M vs Q3 2011N/M vs Q2 2012
EPS Diluted$0.00$0.00 N/M vs Q3 2011N/M vs Q2 2012
Operating Income$99,000N/M
Operating Cash Flowderived$397,000N/M
Free Cash Flowderived$250,000N/M
Margins · derived
Operating margin1.6%+15.2 pt vs Q3 2011
Net margin0.9%+15.1 pt vs Q3 2011
What the release said
The release
Same quarter
| Metric | Q3 2012 | Q3 2011 | Q3 2010 |
|---|---|---|---|
| Revenue | $6.05M | $5.87M | $6.51M |
| Net Income | $54.00K | -$837.00K | $124.00K |
| EPS Diluted | $0.00 | -$0.01 | $0.00 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR